Raymond James Financial Inc. Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)

Raymond James Financial Inc. purchased a new position in Grifols, S.A. (NASDAQ:GRFS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,251 shares of the biotechnology company’s stock, valued at approximately $91,000.

Several other large investors have also bought and sold shares of GRFS. R Squared Ltd acquired a new stake in shares of Grifols during the fourth quarter valued at about $28,000. GAMMA Investing LLC increased its holdings in shares of Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 1,527 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 4,970 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Grifols during the fourth quarter valued at approximately $77,000. Finally, Orion Portfolio Solutions LLC purchased a new position in shares of Grifols during the fourth quarter valued at approximately $119,000.

Grifols Stock Performance

NASDAQ:GRFS opened at $7.86 on Wednesday. The business’s 50-day moving average price is $7.31 and its two-hundred day moving average price is $7.64. Grifols, S.A. has a twelve month low of $5.79 and a twelve month high of $9.96. The stock has a market cap of $5.40 billion, a P/E ratio of 6.72 and a beta of 0.44. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley initiated coverage on Grifols in a research report on Wednesday, February 12th. They issued an “overweight” rating on the stock.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.